HYBIO(SZ:300199) GLP1减重宝典·2025-05-13 15:13Core Viewpoint - The collaboration between Hanyu Pharmaceutical and Shenzhen Carbon Cloud Smart Peptide Technology Co., Ltd. aims to develop a novel peptide drug targeting GLP-1R/GIPR/GCGR for metabolic disease treatment, particularly for weight control [2][3]. Group 1: Collaboration Details - Hanyu Pharmaceutical will handle preclinical research, IND application, clinical trials, and product registration, covering associated costs [3]. - Carbon Cloud Smart Peptide will be responsible for molecular screening and will bear all development costs during this process [3]. - Hanyu Pharmaceutical will pay up to 38 million yuan in milestone payments to Carbon Cloud Smart Peptide and will share revenue based on sales, with a maximum of 10% for North America and 3% for other global regions [3]. Group 2: Market Position and Product Development - Hanyu Pharmaceutical has established a strong position in the GLP-1 market, particularly with its experience in the development of liraglutide and other peptide products [4]. - The collaboration marks Hanyu Pharmaceutical's entry into the innovative research frontier of weight loss drugs, enhancing its global standing in the GLP-1 sector [4]. - The new drug is expected to show significant weight loss effects in preclinical studies, outperforming existing treatments like terzepatide in specific metrics [5][6].